OWCP - OWC Pharmaceutical Research Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.20
-0.01 (-4.67%)
At close: 3:50PM EDT
Stock chart is not supported by your current browser
Previous Close0.21
Open0.21
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.19 - 0.21
52 Week Range0.19 - 0.67
Volume167,670
Avg. Volume431,140
Market Cap29.552M
Beta-10.59
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire22 days ago

    OWC Pharmaceutical Research Corp. Completes First Part of Cannabis-Based Ointment Safety Study

    OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, yesterday announced a successful completion of the first part of its Phase I, placebo controlled, maximal dose study (the "Psoriasis Study") to determine the safety and tolerability of topical ointment containing medical grade cannabis (the "Topical Ointment") in healthy volunteers. The study is being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center. Sheba is a university-affiliated hospital that serves as Israel's national medical center and is one of the leading integrated medical centers in the Middle East.

  • PR Newswirelast month

    OWC Pharmaceutical Research Corp Completes Development of Next Generation Orally-Disintegrating Tablet

    RAMAT GAN , Israel , June 13, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, ...

  • PR Newswire3 months ago

    OWC Pharmaceutical Research Corp Raises $5 Million in Preferred Stock Sale to Institutional Investor

    OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the closing of the sale of $5 million of convertible preferred stock to an institutional investor. The preferred stock is convertible into OWCP common stock at a price of $0.20 per share. The company also issued warrants to purchase 12.5 million shares of common stock to the investor.

  • OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
    PR Newswire4 months ago

    OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders

    PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders. In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the "Company"). The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.

  • OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer
    PR Newswire5 months ago

    OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer

    RAMAT GAN, Israel, Feb. 20, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO). Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry.

  • PR Newswire6 months ago

    OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference

    OWC Pharmaceutical Research Corp. [OWC Pharma](OWCP) is pleased to announce it will be a Diamond Sponsor at the 2018 Wall Street Conference. This is second consecutive year OWC Pharma will be attending this prestigious investment conference to be held on February 21st , 2018 at the Hilton Doubletree Hotel & Convention Center in Boca Raton, Florida. The Wall Street Conference is one of the premiere conferences in the venture capital arena and Small Cap marketplace.

  • OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet
    PR Newswire7 months ago

    OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet

    PETACH TIKVA, Israel, Dec. 21, 2017 /PRNewswire/ -- In December 2017, OWC Pharmaceutical Research Corp (OWCP) received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. In October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis.

  • PR Newswire10 months ago

    OWC Pharma Issues Chairman's Letter to Shareholders

    OWC Pharma (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders. Following my recent appointment as Chairman at OWC Pharma (OWCP), it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters.

  • PR Newswirelast year

    OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active chairman of the board of directors. Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.